{"cik":2075320,"taxonomy":"us-gaap","tag":"LiabilitiesCurrent","label":"Liabilities, Current","description":"Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.","entityName":"Polaryx Therapeutics, Inc.","units":{"USD":[{"end":"2024-12-31","val":289000,"accn":"0001213900-26-033064","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-24","frame":"CY2024Q4I"},{"end":"2025-12-31","val":605000,"accn":"0001213900-26-033064","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-24"},{"end":"2025-12-31","val":605000,"accn":"0001213900-26-056973","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-15"},{"end":"2025-12-31","val":605000,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2025Q4I"},{"end":"2026-03-31","val":1014000,"accn":"0001213900-26-056973","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-15","frame":"CY2026Q1I"},{"end":"2026-06-30","val":873000,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2026Q2I"}]}}